Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The tumor-suppressor ING3 has been shown to be involved in tumor transcriptional regulation, apoptosis and the cell cycle. Some studies have demonstrated that ING3 is dysregulated in several types of cancers. However, the expression and function of ING3 in human hepatocellular carcinoma (HCC) remains unclear. The aim of this study is to investigate ING3 expression in hepatic tumors and its clinical relevance in hepatic cancer. The expression of ING3 protein was examined in 120 dissected HCC tissues and 47 liver tissues adjacent to the tumor by immunohistochemical assays and confirmed by Western blot analysis in 20 paired frozen tumor and non-tumor liver tissues. The relationship between ING3 staining and clinico-pathological characteristics of HCC was further analyzed. The mRNA expression of ING3 in the dissected tissues was also analyzed by reverse transcriptase polymerase chain reaction (RT-PCR) and realtime PCR. Both mRNA and protein concentrations of ING3 were found to be downregulated in the majority of HCC tumors in comparison with matched non-tumor hepatic tissues. Analysis of the relationship between ING3 staining and clinico-pathological characteristics of HCC showed that the low expression of ING3 protein is correlated with more aggressive behavior of the tumor. Kaplan-Meier curves demonstrated that patients with a low expression of ING3 have a significantly increased risk of shortened survival time. In addition, multivariate analysis suggested that the level of ING3 expression may be an independent prognostic factor. Our findings indicate that ING3 may be an important marker for human hepatocellular carcinoma progression and prognosis, as well as a potential therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1258/ebm.2011.011346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of ING3 in the Prostate Leads to Activation of DNA Damage Repair Markers.
Cancers (Basel)
March 2025
Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
Background/objectives: The inhibitor of growth family member 3 (ING3) acts as an epigenetic reader through physical interactions with histone-modifying enzymes and subsequent chromatin remodelling processes. It is involved in various cellular functions, such as cell cycle control, cell growth, and apoptosis. Although ING3 was assigned tumour suppressor candidate status in some types of cancers, including prostate cancer, some studies suggest it acts to promote growth.
View Article and Find Full Text PDFMolecular characterization of human HSPCs with different cell fates in vivo using single-cell transcriptome analysis and lentiviral barcoding technology.
Clin Transl Med
November 2024
BGI, Shenzhen, China.
Hematopoietic stem and progenitor cells (HSPCs) possess the potential to produce all types of blood cells throughout their lives. It is well recognized that HSPCs are heterogeneous, which is of great significance for their clinical applications and the treatment of diseases associated with HSPCs. This study presents a novel technology called Single-Cell transcriptome Analysis and Lentiviral Barcoding (SCALeBa) to investigate the molecular mechanisms underlying the heterogeneity of human HSPCs in vivo.
View Article and Find Full Text PDFDecreased Nuclear Immunoexpression of ING3 is a Frequent Event in Lip Carcinogenesis.
Head Neck Pathol
October 2024
Department of Oral Pathology, Federal University of Rio Grande do Norte, Av. Senador Salgado Filho, Lagoa Nova, Natal, 1787, CEP 59056-000, RN, Brazil.
Purpose: Evaluate the immunohistochemical expression of the ING3 in actinic cheilitis and squamous cell carcinoma of the lower lip.
Methods: Forty-five specimens of actinic cheilitis and 48 specimens of squamous cell carcinoma of the lower lip were submitted to immunohistochemical detection of ING3. The protein expression in different cellular sublocations was compared between the two groups, and associations with the clinicopathological variables were analyzed.
ING3 inhibits the malignant progression of lung adenocarcinoma by negatively regulating ITGB4 expression to inactivate Src/FAK signaling.
Cell Signal
May 2024
Shandong Provincial Third Hospital Medical Laboratory, Shandong University, Jinan City, Shandong Province 250031, China.
Lung adenocarcinoma (LUAD) is the most commonly diagnosed subtype of lung cancer worldwide. Inhibitor of growth 3 (ING3) serves as a tumor suppressor in many cancers. This study aimed to elucidate the role of ING3 in the progression of LUAD and investigate the underlying mechanism related to integrin β4 (ITGB4) and Src/focal adhesion kinase (FAK) signaling.
View Article and Find Full Text PDFThe ubiquitin E3 ligase MDM2 induces chemoresistance in colorectal cancer by degradation of ING3.
Carcinogenesis
October 2023
General Surgery Department, Wujin Hospital Affiliated with Jiangsu University, The Wujin Clinical College of Xuzhou Medical University, Changzhou 213004, P. R. China.
Article Synopsis
- Chemoresistance in colorectal cancer (CRC) complicates treatment, and this study focuses on the role of MDM2, a ubiquitin E3 ligase, in influencing CRC cell growth and response to chemotherapy.
- Researchers analyzed the interaction between MDM2 and the transcription factor ING3, discovering that MDM2 reduces ING3 protein stability through a process called ubiquitination, which leads to increased cell proliferation and decreased apoptosis in CRC cells.
- The study also confirms, through experiments in mice, that the combined effects of MDM2 and reduced ING3 expression contribute to tumor growth and chemoresistance in colorectal cancer.